BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23317212)

  • 1. Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men.
    Zheng XY; Zhang P; Xie LP; You QH; Cai BS; Qin J
    Asian Pac J Cancer Prev; 2012; 13(11):5529-33. PubMed ID: 23317212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction.
    Choi SY; Chang IH; Kim YS; Kim TH; Kim W; Myung SC
    Urology; 2011 Oct; 78(4):874-9. PubMed ID: 21791361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL.
    Zheng XY; Xie LP; Wang YY; Ding W; Yang K; Shen HF; Qin J; Bai Y; Chen ZD
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1207-10. PubMed ID: 18446367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Int J Urol; 2005 Oct; 12(10):881-5. PubMed ID: 16323981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of the transition zone index for identification of prostate cancer in Chinese men with intermediate PSA levels.
    Qi TY; Chen YQ; Jiang J; Zhu YK; Yao XH; Wang XJ
    Int Urol Nephrol; 2012 Jun; 44(3):807-15. PubMed ID: 22311386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
    Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
    Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population.
    Wu YS; Wu XB; Zhang N; Jiang GL; Yu Y; Tong SJ; Jiang HW; Mao SH; Na R; Ding Q
    Asian J Androl; 2018; 20(4):324-329. PubMed ID: 29405172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study.
    Lin YR; Wei XH; Uhlman M; Lin XT; Wu SF; Diao PF; Xie HQ; Xie KJ; Tang P
    Asian J Androl; 2015; 17(3):503-7. PubMed ID: 25475661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
    Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
    Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
    Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ
    Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Wolters T; Roobol MJ; Bangma CH; Schröder FH
    Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of serum level of prostate-specific antigen adjusted for the transition zone volume in early detection of prostate cancer.
    Ferreira MD; Koff WJ
    Int Braz J Urol; 2005; 31(2):137-45; discussion 146. PubMed ID: 15877833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium.
    Song ZJ; Qian JK; Yang Y; Wu HX; Wang MY; Jiang SY; Wang FB; Zhang W; Chen R;
    Asian J Androl; 2021; 23(3):300-305. PubMed ID: 33208562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA density and prostate cancer detection.
    Saema A; Kochakarn W; Lertsithichai P
    J Med Assoc Thai; 2012 May; 95(5):661-6. PubMed ID: 22994025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
    Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.